chronous and metachronous PDAC). Integrated clinical, pathological, and mutational analyses, using TP53 and SMAD4 immunostaining and targeted next-generation sequencing of 50 cancer-related genes, were conducted to examine the intertumor relationships. Four of the nine patients were assessed as having undergone multicentric carcinogenesis because of heterogeneity of immunohistochemical and/or mutation characteristics. In contrast, tumors in the other five patients showed intertumor molecular relatedness. Two of these five patients, available for matched sequencing data, showed two or more shared mutations. Moreover, all the smaller nodules in these five patients showed identical TP53 and SMAD4 expression patterns to the corresponding main tumors. Consequently, these five patients were considered to have undergone intrapancreatic metastasis. None of the five smaller nodules arising from intrapancreatic metastasis was accompanied by pancreatic intraepithelial neoplasia, and three of them were tiny (≤1mm). Patients whose tumors resulted from intrapancreatic metastasis appeared to have higher disease stages and worse outcome than those with tumors from multicentric carcinogenesis. Our results provide insight into pancreatic carcinogenesis, showing that the development of multiple PDAC involves distinct evolutionary paths that potentially affect patient prognosis.
| INTRODUC TI ON
Pancreatic ductal adenocarcinoma develops through sequential genetic and epigenetic alterations in a number of driver genes, including KRAS, TP53, SMAD4, and CDKN2A. [1] [2] [3] [4] [5] [6] [7] Accumulating evidence from engineered mouse models attests to the importance of PanIN as a precursor of PDAC. [8] [9] [10] [11] [12] [13] Previous studies have shown that incidental multifocal PanIN are frequently observed in the adult pancreas within surgical specimens and autopsy cases. [14] [15] [16] Strict surveillance of high-risk groups, such as familial pancreatic cancer kindreds, those with hereditary neoplastic syndromes, and PDAC patients following pancreatectomy for PDAC, suggests that spatial and temporal multicentric carcinogenesis involves pancreatic cancer development [17] [18] [19] [20] in a manner similar to that of hepatocellular carcinoma and colorectal cancer. 21, 22 Because of the aging population and recent advances in technology and treatments for PDAC, the number of newly diagnosed patients and long-term survivors after curative surgery for PDAC is growing. Consequently, in oncology clinics, there are increased opportunities to identity synchronous and/or metachronous multiple PDAC.
The propensity of orthotopic colonization in several types of cancers, including malignant melanoma, lung cancer, and liver cancer, is exemplified by tissue tropisms of metastasizing tumor cells in a process known as the "seed and soil hypothesis". 23, 24 Previous reports have suggested that intrapancreatic metastasis may serve as another evolutionary scenario for multiple PDAC. 25, 26 A recent study has suggested that precancerous intraepithelial neoplasms can spread contiguously or disseminate discontiguously along the pancreatic ductal system to form multifocal clonal lesions.
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Therefore, we hypothesized that two distinct pathways, multicentric carcinogenesis and intrapancreatic metastasis, might contribute to the formation of multiple PDAC. A previous study by
Oguro et al reported that 21 of 393 patients had synchronous multiple PDAC as a result of intrapancreatic metastasis and that the presence of this histological finding was a worse prognostic factor, 26 although this previous study was conducted based on histomorphological features without any molecular assessment. Two recent studies using genetic testing on pancreatic cancer arising in the remnant pancreas after pancreatectomy identified recurrent cases as a result of multicentric occurrence. 17, 28 In order to expand these prior studies, we analyzed not only metachronous tumors but also synchronous cases and integrated clinicopathological characteristics of multiple PDAC with molecular information, using NGS and IHC. In addition, we further explored the prognostic associations of the results with patient outcome to verify the clinical usefulness of distinguishing intrapancreatic metastasis from multicentric occurrence. with synchronous PDAC, one patient (two nodules) with metachronous PDAC, and two patients (six nodules) with both synchronous and metachronous PDAC (Figure 1 ). We conducted a histological review and confirmed that all the synchronous lesions were more than or equal to 10 mm apart with no connection between them (Table 1) . For the three patients with metachronous tumors, pancreatic cut margin statuses at the initial surgery were negative. NGS analysis of tumors from the nine patients found no GNAS mutation, a major driver of IPMN tumorigenesis. [31] [32] [33] None of the nine patients had a family history of pancreatic cancer in first-degree relatives. One patient (MPKO09) had a pancreaticobiliary maljunction.
| MATERIAL S AND ME THODS
Histological examinations were reviewed by two study pathologists (YM and MS). Tumor-associated PanIN was defined by the presence of PanIN2 or PanIN3 lesion in or around each PDAC nodule. Intraductal carcinoma spread (as known as "cancerization") was carefully examined and was not considered as the presence of tumor-associated PanIN. 16, 34 The current study included two patients (MPKO07 and MPKO08) who were described in a previous case report 25 in which these two patients were diagnosed with intrapancreatic metastases on the basis of the following histopathological criteria: lesions were at least 10 mm apart with no connection between them; each lesion showed similar histological findings; there was no PanIN lesion in or around the smaller, recessive lesions; and the histological type of the smaller lesions was uniform. The TNM staging system used in this study was that defined by the American Joint Committee on Cancer, 8th edition. 35 The study was approved by the institutional review board of Keio University, and was con- and an anti-SMAD4 mouse monoclonal antibody (clone B-7, dilution, 1:100; Santa Cruz Biotechnologies) were used as the primary antibodies. On the basis of previously established criteria, 36 tumors that showed weak, heterogeneous nuclear TP53 staining were defined as "intact", whereas those showing strong nuclear staining were classified as "altered". In the current dataset, no tumor showed complete absence of nuclear TP53 expression. For SMAD4, tumors were classified as "intact" if there was nuclear/cytoplasmic staining within the tumor, or "lost" if there was complete absence of staining, as previously described. 37, 38 No tumor had missing information on IHC data. Table S1 shows correlations between immunohistochemical expression patterns and mutation statuses for TP53 and SMAD4. All the eight tumors with altered TP53 expression had mutations in the TP53 allele, whereas six of 11 tumors with loss of SMAD4 protein expression were called "wild type" by NGS analysis.
| Next-generation sequencing
After macroscopic dissection, genomic DNA was extracted from tumor and non-tumor areas of FFPE tissue sections using a QIAamp DNA FFPE Tissue Kit (Qiagen). 39, 40 Integrity of purified DNA from FFPE samples was assessed using the TaqMan RNase P Detection
Reagents kit and the FFPE DNA QC Assay (Thermo Fisher Scientific).
Barcoded libraries were generated from 10 ng DNA per sample using 
Alignment was visually inspected with the Integrative Genomics Viewer software (http//www.broad insti tute.org/igv). We were not able to obtain mutation profiles from five nodules as a result of low DNA quality (one specimen was surgically resected more than 10 years ago), limited tumor size (three nodules were less than or equal to 1 mm in diameter), or tumor purity (one nodule had less than 5% tumor purity because of neoadjuvant therapy Figure S2 ).
| Statistical analysis
Survival curves were estimated using the Kaplan-Meier method.
The survival curves for patients with multicentric carcinogenesis and intrapancreatic metastasis were compared using the log-rank test. Outcome endpoint for distant metastasis-free survival was the diagnosis of metastasis to distant organs (other than the pancreas or peripancreatic lesions). Death as a result of pancreatic cancer was the endpoint for cancer-specific survival and death as a result of other causes was censored. Survival time was defined as the period from the date of surgery that showed multiple PDAC to event (death or recurrence) or to the end of follow up. Fisher's exact test was used to compare the differences in mutation rates between patients with multicentric carcinogenesis and those with intrapancreatic metastasis. For all statistical analyses, P values were twosided, and P < .05 was defined as significant. All statistical analyses were carried out using EZR version 1.37 (Saitama Medical Center, Jichi Medical University), 43 which is a graphic user interface for R (The R Foundation for Statistical Computing).
| RE SULTS

| Clinicopathological and genetic relationships between tumors in patients with multiple PDAC
We analyzed 20 tumors from nine patients who had synchronous and/or metachronous PDAC. (Table S2) .
Moreover, immunohistochemical examination showed distinct patterns between these two synchronous tumors in terms of TP53 and Mutation profiles of tumor T1 or T2 were unable to be obtained because of low DNA quality and/or considerably limited tumor size/purity.
c Tumor grade was not assigned because tumor cell morphology was severely modified by preoperative chemoradiotherapy.
TA B L E 1 (Continued)
SMAD4 statuses. Therefore, we considered that the two tumors from MPKO01 were independent and likely arose from multifocal origins. Similarly, NGS data indicated no shared mutations between two synchronous tumors in patient MPKO02, which led us to postulate their origins to be independent. Tumor T2 in patient MPKO03
was clinically regarded as a second primary tumor, because it developed in the remnant pancreas 11 years after R0 surgery without any history of recurrence. Indeed, the two tumors from MPKO03
showed different TP53 immunostaining patterns, and both tumors had tumor-associated PanIN lesions.
For patient MPKO04, no shared mutations were detected between T2 and T1 or T3, indicating that tumor T2 was genetically independent of the other two tumors. Among the 50 genes in the NGS panel, we found one mutation in KRAS shared between T1 and T3 in MPKO04; however, the mutation patterns were different in 22
other genes (31 and 20 mutations were detected in tumors T1 and T3, respectively). In particular, the mutation patterns were different in TP53 and SMAD4, which are major driver genes essential for the progression to carcinoma. 44 In addition, the pancreatic resection margin for the initial surgery for MPKO04 was negative, and the anatomical locations were some distance apart (T1, tail; T3, head).
Consequently, we considered the three tumors from MPKO04 as likely being independent.
Mutation analysis uncovered strong intertumor relationships be- Consequently, we considered these tiny nodules from patients MPKO06, MPKO07, and MPKO08 to be orthotopic metastatic daughters.
In summary, we identified four patients (MPKO01-04) who had independent tumors (regarded as "multicentric carcinogenesis") and proposed by previous studies. 25, 26 We did not observe significant differences in mutation rates for any genes examined between the two possible evolutionary paths ( Figure S3 ). Examples of the characteristics of tumors resulting from multicentric carcinogenesis (MPKO02) and intrapancreatic metastasis (MPKO09) are shown in 
| Differences in clinical behavior by etiologies of multiple PDAC
We then compared outcomes and found that disease stages appeared to be higher for intrapancreatic metastasis-associated tumors than tumors resulting from multicentric carcinogenesis ( Table 2 ). All the five patients with intrapancreatic metastasis died of pancreatic cancer, whereas one of the four patients whose tumors resulted from multicentric carcinogenesis died of this disease. Patients with intrapancreatic metastasis had statistically shorter distant metastasis-free survival and cancer-specific survival than those harboring tumors resulting from multicentric carcinogenesis (P = .047 and P = .049, respectively; by log-rank test; Figure 3 ).
| D ISCUSS I ON
Integrated clinical, pathological, and mutational analyses on synchronous and/or metachronous pancreatic cancers suggested two pathogenic pathways for the formation of multiple PDAC: multicentric carcinogenesis and intrapancreatic metastasis. Among the nine patients with multiple PDAC in the current study, we found four cases (44%) of multicentric tumors and five cases (56%) of intrapancreatic metastasis. A recent study analyzed six PDAC arising in the remnant pancreas after surgical resection of primary pancreatic cancers using mutation testing for 11 pancreatic cancer-related genes, and showed that three (50%) of six patients had "true" recurrence whereas two (33%) had independent tumors. 17 These findings are generally consistent with our results. Another recent study analyzed RAS mutations in 14 patients with metachronous PDAC and identified two patients (14%) as having shared mutations; 45 however, the mutation rate for KRAS was considerably low (21%) in that study cohort compared to previous large studies and our current study. [46] [47] [48] These lines of evidence together with our findings indicate that the two distinct evolutionary paths may contribute to the formation of synchronous and/or metachronous PDAC in clinical practice.
Evidence from engineered mouse models and human tissue-based studies has indicated that precursor PanIN initiate multifocally, and several of them can progress to carcinomas that eventually become invasive and metastatic. We determined the pathogenesis of tumors T1 and T3 in patient MPKO04 as multicentric carcinogenesis because they showed differing mutation statuses in 22 of the 23 mutated genes, including major drivers. However, the finding that these two tumors had a common mutation, KRAS p.Q61H, one of common KRAS variants in PDAC populations (prevalence rate, 5.8%), 36 is intriguing. Given the markedly high mutation rates in tumors of patient MPKO04, a by-chance scenario of this matched mutation is most likely. A recent study has suggested that the precancerous cells in PanIN move through the pancreatic ductal system and initiate multicentric nodules in the pancreas. 27 Therefore, we presume an alternative scenario where a precancerous ancestor harboring KRAS p.Q61H disseminated via the pancreatic duct to form precursors of tumors T1 and T3, followed by sequential accumulation of mutations in different sets of driver genes, including TP53
and SMAD4, resulting in the formation of genetically independent invasive cancers.
The current study showed that patients with intrapancreatic metastasis had statistically shorter distant metastasis-free survival and shorter pancreatic cancer-specific survival than did patients with multiple PDAC of multicentric carcinogenesis. Based We recognize certain limitations in this study. First, we were not able to obtain NGS data from some tissue samples despite repeated DNA extractions using archival FFPE and frozen tissues. However, in such cases, clinicopathological findings from IHC and morphological investigation helped us to clarify the intertumor relationships.
Second, the number of cases was limited in this retrospective study.
Nonetheless, our primary hypothesis testing was whether two potential pathways (multicentric carcinogenesis and intrapancreatic metastasis) might contribute to the formation of multiple PDAC. In The genomic characterization of PDAC is beginning to be implemented in oncology clinics in an effort to harness potential therapeutic opportunities against this deadly cancer. 52 Our data suggest that the clinicopathological and genetic assessments of multiple PDAC are helpful to distinguish tumors resulting from multifocal carcinogenesis from those resulting from intrapancreatic metastasis; the latter type likely have a dismal prognosis. This study provides insights into the origins of multiple PDAC and, once validated, could inform clinical practice by guiding treatment strategies against pancreatic cancer in the era of precision medicine. 
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